Overview

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Status:
Completed

Trial end date:
2018-11-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.

Phase:

Phase 2

Details

Lead Sponsor:

R-Pharm

Collaborator:

Almedis

Treatments:

Ritonavir